EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An activin receptor-like kinase 1–governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases

Mehrnaz Safaee Talkhoncheh, Jonas Sjölund, Paulina Bolivar, Ewa Kurzejamska, Eugenia Cordero, Teia Vallès Pagès, Sara Larsson, Sophie Lehn, Gustav Frimannsson, Viktor Ingesson, Sebastian Braun, Jessica Pantaleo und 7 weitere

Journal of Clinical Investigation · 03.03.2025 · 135 (5)

DOI: 10.1172/jci183086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 14.01.2025. Verfasst von Mehrnaz Safaee Talkhoncheh und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University Cancer Centre, Medicon Village, Lund University, Lund, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Activin Receptors, Type I, Tumor-Associated Macrophages, Monocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancerfonden, Vetenskapsrådet, Knut och Alice Wallenbergs Stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The biology centered around the TGF-β type I receptor activin receptor-like kinase (ALK) 1 (encoded by ACVRL1 ) has been almost exclusively based on its reported endothelial expression pattern since its first functional characterization more than 2 decades ago. Here, in efforts to better define the therapeutic context in which to use ALK1 inhibitors, we uncover a population of tumor-associated macrophages (TAMs) that, by virtue of their unanticipated Acvrl1 expression, are effector targets for adjuvant antiangiogenic immunotherapy in mouse models of metastatic breast cancer. The combinatorial benefit depended on ALK1-mediated modulation of the differentiation potential of bone marrow–derived granulocyte-macrophage progenitors, the release of CD14 + monocytes into circulation, and their eventual extravasation. Notably, ACVRL1 + TAMs coincided with an immunosuppressive phenotype and were overrepresented in human cancers progressing on therapy. Accordingly, breast cancer patients with a prominent ACVRL1 hi TAM signature exhibited a significantly shorter survival. In conclusion, we shed light on an unexpected multimodal regulation of tumorigenic phenotypes by ALK1 and demonstrate its utility as a target for antiangiogenic immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsActivin Receptors, Type ITumor-Associated MacrophagesMonocytesNeoplasm ProteinsFemaleAnimalsHumansMiceNeoplasm MetastasisCell Line, TumorCell LineageActivin Receptors, Type II

Stichwörter der Autor:innen

Breast cancerCancer immunotherapyEndothelial cellsImmunologyOncology

Substanzen

Activin Receptors, Type IACVRL1 protein, humanAcvrl1 protein, mouseNeoplasm ProteinsActivin Receptors, Type II

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University Cancer Centre, Medicon Village, Lund University, Lund, Sweden.
  • Department of Laboratory Medicine, Karolinska Institutet, Solna, Sweden.
  • Lund University Diabetes Centre, Clinical Research Center, Lund University, Lund, Sweden.
  • Biotech Research and Innovation Center, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Centre, Lund University, Lund, Sweden.
  • P2 Biopharma Consulting, North Reading, Massachusetts, USA.

Förderung

  • Cancerfonden
  • Vetenskapsrådet
  • Knut och Alice Wallenbergs Stiftelse
  • Region Skåne
  • Göran Gustafssons Stiftelser
  • Mats Paulssons Stiftelse
  • Cancera foundation
  • Fru Berta Kamprads Stiftelse

Zitieren

APA

Safaee Talkhoncheh, M., Sjölund, J., Bolivar, P., Kurzejamska, E., Cordero, E., Vallès Pagès, T., Larsson, S., Lehn, S., Frimannsson, G., Ingesson, V., Braun, S., Pantaleo, J., Oudenaarden, C., Lauss, M., Pearsall, R. S., Jönsson, G., Rolny, C., Bocci, M., & Pietras, K. (2025). An activin receptor-like kinase 1–governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases. Journal of Clinical Investigation, 135(5). https://doi.org/10.1172/jci183086

Vancouver

Safaee Talkhoncheh M, Sjölund J, Bolivar P, Kurzejamska E, Cordero E, Vallès Pagès T, et al. An activin receptor-like kinase 1–governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases. Journal of Clinical Investigation. 2025;135(5). doi:10.1172/jci183086

BibTeX
@article{SafaeeTalkhoncheh2025,
  author = {Safaee Talkhoncheh, Mehrnaz and Sjölund, Jonas and Bolivar, Paulina and Kurzejamska, Ewa and Cordero, Eugenia and Vallès Pagès, Teia and Larsson, Sara and Lehn, Sophie and Frimannsson, Gustav and Ingesson, Viktor and Braun, Sebastian and Pantaleo, Jessica and Oudenaarden, Clara and Lauss, Martin and Pearsall, R Scott and Jönsson, Göran and Rolny, Charlotte and Bocci, Matteo and Pietras, Kristian},
  title = {An activin receptor-like kinase 1–governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {5},
  doi = {10.1172/jci183086}
}
Kostenlos starten →